Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

In a multicenter cohort of 3,980 oral cavity squamous cell carcinoma patients, preoperative clinical and tumor features—including age, comorbidity, tumor subsite, size, clinical stage, and biopsy grade—predicted receipt and intensity of adjuvant therapy, with a predictive model AUC of 0.84.
Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis
Posted inGastroenterology news Oncology

Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

A BMJ systematic review and network meta‑analysis of 60 studies (4,633 patients) finds doublet chemotherapy combined with anti‑EGFR/BRAF therapy offers the best first‑line overall survival for advanced BRAF‑mutant colorectal cancer; anti‑EGFR/BRAF regimens remain optimal after prior therapy.
Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority
Posted innews Oncology Otorhinolaryngology

Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority

A multicenter propensity-matched cohort comparing adjuvant proton beam radiotherapy (PBRT) with intensity-modulated radiotherapy (IMRT) for olfactory neuroblastoma found no definitive differences in local control, recurrence-free survival, overall survival, or clinically meaningful reductions in grade ≥2 radiation toxicities, but estimates were imprecise.
Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice
Posted innews Oncology Otorhinolaryngology

Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice

An international multicenter cohort of 1,883 patients with radiologically growing vestibular schwannomas treated first‑line with radiotherapy showed a 10‑year tumor control rate of 76.1% (primary definition). Control estimates varied widely by growth definition, underscoring the clinical importance of outcome metrics.
Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know
Posted inCardiology news Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Trial selection and monitoring practices limit generalizability; baseline cardiac assessment and individualized surveillance remain essential.
Therapist-Guided e‑Health Cuts Fear of Cancer Recurrence in Colorectal Survivors: A Randomized Trial Shows Clinically Meaningful Benefits
Posted inAI news Oncology

Therapist-Guided e‑Health Cuts Fear of Cancer Recurrence in Colorectal Survivors: A Randomized Trial Shows Clinically Meaningful Benefits

A Danish RCT of TG‑iConquerFear, a 10‑week therapist‑guided online program for colorectal cancer survivors with clinical fear of cancer recurrence (FCR), reduced FCR scores substantially compared with augmented self‑help at 3 months; the between‑group effect was clinically meaningful (Cohen d 0.62).
Neural Networks Predict Survival for Older Adults With Head and Neck Cancer — Useful, but Not Yet Practice-Changing
Posted innews Oncology Otorhinolaryngology

Neural Networks Predict Survival for Older Adults With Head and Neck Cancer — Useful, but Not Yet Practice-Changing

An international cohort study developed and externally validated artificial neural networks that stratify older adults with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiation. Models showed moderate discrimination (OS AUC 0.68, PFS AUC 0.64) with HPV status, kidney function, ECOG, and nodal stage among top predictors.